Imaging for predicting recurrence in digestive system tumors
The Application of Molecular Probe Targeting Fibroblast Activation Protein in Malignant Tumor of Digestive System
Zhongnan Hospital · NCT05420558
This study is testing a new type of imaging to see if it can better predict the return of digestive system tumors after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Zhongnan Hospital (other) |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05420558 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of fibroblast activation protein inhibitor PET/CT imaging in predicting early postoperative recurrence of malignant tumors in the digestive system. It focuses on assessing the diagnostic performance of this novel imaging technique in detecting both primary tumors and metastatic lesions. By utilizing qualitative and quantitative analyses, the study seeks to improve upon traditional FDG PET/CT imaging, which has limitations in sensitivity and specificity for certain types of gastrointestinal cancers. The study is conducted at a single center, Zhongnan Hospital of Wuhan University.
Who should consider this trial
Good fit: Ideal candidates include patients with suspected or newly diagnosed gastrointestinal cancer or other malignant tumors of the digestive system.
Not a fit: Patients who are pregnant, breastfeeding, or have conditions that prevent them from tolerating PET/CT examinations may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could lead to earlier detection of tumor recurrence, improving patient outcomes in gastrointestinal cancer.
How similar studies have performed: While traditional imaging methods have been widely used, the specific application of FAPI PET/CT for this purpose is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Voluntarily participate and sign the informed consent. 2. Patients with suspected or new diagnosed gastrointestinal cancer or other malignant tumor of digestive system. 3. Complete clinical information, biochemical examination results, CT and/or MRI imaging examination, pathological information, and clinical/imaging follow-up data. Exclusion Criteria: 1. Female patient who plan to become pregnant within 6 months, or pregnant or breast-feeding women. 2. Allergic constitution. 3. Those who are in poor general condition and cannot tolerate PET/CT examination. 4. The researchers believe that he or she is not suitable to participate in this study.
Where this trial is running
Wuhan, Hubei
- Zhongnan Hospital of Wuhan University — Wuhan, Hubei, China (RECRUITING)
Study contacts
- Study coordinator: Chongjiao Li, MD, PhD
- Email: LCJ0301@163.com
- Phone: +86-18827093900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Gastrointestinal Cancer, fibroblast activation protein inhibitor, positron emission tomography, gastrointestinal cancer, digestive system tumor, recurrence, metastases, prognosis